“

Recently we have seen drug companies setting very high prices for promising immunotherapies, including nivolumab, there is no question that this pioneering and innovative treatment improves and extends the life of patients with non-small cell lung cancer – a disease that has very limited treatment options – but at this price it is very clearly too expensive.